Take-home naloxone as integral part of toolkits for public health providers: priorities across settings Dagmar Hedrich, EMCDDA Lisbon, 25 October 2017.

Slides:



Advertisements
Similar presentations
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Advertisements

Cancer inequalities in Europe Kielce, Polish conference on cancer, 13/15 June 2011 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit.
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
1 Survey Data in ECA : Frequency, Coverage, Consistency and Access By Victor Sulla ECS-PE.
European integration 1www.ecb.europa.eu © Progress of European integration 1952ECSC European Coal and Steel Community 1958 EEC and EURATOM European Economic.
European Union The Gay Perspective SCOREBOARD V 2.0.
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic.
Session 1: Child poverty outcomes and main factors behind International benchmarking and key challenges for Member States András Gábos TARKI Social Research.
Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.
Gender Equality is key towards the eradication of Violence against Women.
Drug-related deaths Phil Conley Health Improvement Programme Manager September 2015.
Dagmar Hedrich, Linda Montanari, Alessandra Bo, Bruno Guarita, Chloé Carpentier, Isabelle Giraudon, Luis Royuela, Lucas Wiessing « Good prison health –
Progress of European integration
Drugs and Prison in Europe: State of Play
Programme for International Student Assessment
Rome Cardiology Forum 2014 Update on life-style and cardiovascular prevention The dimension of the problem Rome Cardiology Forum January 29, 2014.
Table 1. New HIV diagnoses by country, EU/EEA, 2010–2014
6% of adults had used one or more illicit drugs in last 12 months.
Gas Regional Initiatives
Drug-induced deaths in Europe: enhanced analysis of numbers, trends and contexts to identify possible artefacts and gain better insights into epidemiology.
Table 1. Cases of reported, confirmed cases of invasive meningococcal disease: number and rate per population, EU/EEA, 2010–2014 Country
Country Cases Rate National data Report type
Table 1. Reported invasive Haemophilus influenzae cases: number and rate per population, EU/EEA, 2010–2014 Country Con­firmed.
MODULE 2- EPIDEMIOLOGY OF DRUG USE IN THE AMERICAS
Eurojust cases involving crimes against children
Country Cases Rate National data Report type
GTE+ Winter Outlook 2008/2009 Final Version,
Table 1. Criteria for differentiating acute and chronic hepatitis B
Table 1. Cases of reported, confirmed cases of invasive pneumococcal disease: number and rate per population, EU/EEA, 2010–2014 Country
Isabelle Giraudon Lisbon, 25 October 2017
Country Cases Rate National data Report type
Cases Rate National data Report type
PRODUCTION RETAIL SALES CONSUMER PRICES
Statistical indicators for the Bologna implementation report
Ag.no. 15 Lessons from the 2015 A65 exercise
HIV/AIDS Surveillance in Europe 2011
Country Cases Rate National data Report type
CAF Activities.
Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2011–2015 Country
MSFD Scoreboard Status at 23 November 2012 Belgium Bulgaria Cyprus
SBS Compliance report item 3 of the agenda
Table 1. Number and rate of reported confirmed gonorrhoea cases per population, EU/EEA, 2010–2014 Country Cases Rate Austria.
Table 1. Number and rate of reported confirmed chlamydia cases per population, EU/EEA, 2010–2014 Country Cases Rate Austria.
Statistical indicators on international student mobility Targets in balanced mobility and inbound mobility Meeting of the BFUG working-group on Mobility.
ESF FINANCIAL EXECUTION ESF Technical Working Group Meeting June 2018
Country Cases Rate National data Report type
Country Cases Rate National data Report type
NUAC meeting May Overview of data - Metadata
LAMAS October 2017 Agenda Item 3.2 Labour Cost Indices state of play Daniel Iscru Hubertus Vreeswijk.
PRODUCTION RETAIL SALES CONSUMER PRICES
Marine Strategy Framework Directive: Transposition and Implementation
Marine Strategy Framework Directive: Status of reporting
ESF FINANCIAL EXECUTION ESF Technical Working Group Meeting June 2018
Ag Family Budget Survey
European economic and Social Committee
Programme adoptions Cohesion Policy:
Marine Strategy Framework Directive: Status of reporting
Marine Environment and Water Industry Unit
Table 1. Locally acquired cases of West Nile fever: number and rate per population, EU/EEA, 2010–2014 Country Cases Rate.
Textile. Clothing. Leather. Shoes.
DG Environment, Unit D.2 Marine Environment and Water Industry
ESF FINANCIAL EXECUTION ESF Technical Working Group Meeting June 2018
Country Cases Rate National data Report type
Social Reintegration in Europe
Country Cases Rate National data Report type
Marine Strategy Framework Directive: Status of reporting
Annual Epidemiological Report for 2017 Sexually Transmitted Diseases - chlamydia - gonorrhoea - lymphogranuloma venereum - (congenital) syphilis.
Presentation transcript:

Take-home naloxone as integral part of toolkits for public health providers: priorities across settings Dagmar Hedrich, EMCDDA Lisbon, 25 October 2017 LisbonAddictions2017, Structures Session 25

Drug-induced deaths reported in Europe in 2015 In the EU, someone dies from a drug overdose every 70 minutes ( USA in 2016 = 8 min). Polydrug intoxication is the norm, but background of heroin and other opioids involvement in most cases. E.g. in Finland, the average number of drugs found was 5 Other factors associated with fatal and non-fatal OD: Not being in drug treatment Injecting use Simultaneous use of alcohol, benzodiazepines, other drugs Poor mental health Homelessness Previous overdose Using drugs alone Time immediately after release from prison or discharge from drug treatment (Purity) and availability Provision of harm reduction/treatment services

Overdose deaths are increasing again Trends in overdose deaths 2006-2015 Overdoses: The numbers are likely to be conservative, as national data may be affected by under-reporting or under-ascertainment of drug-induced deaths. Opiods: Opioids, mainly heroin or its metabolites, are present in the majority of drug-induced deaths reported in Europe. In the 23 countries providing data in 2009 or 2010, opioids accounted for the large majority of all cases, with 15 countries reporting proportions of equal to or over 80%, of which six were over 90%. [i] Table DRD-1 part ii. 23 countries are all 30 countries minus BE (because most recent data was 2005) and 6 countries where no toxico data on % of opioid was available: BU, DE, HL, SP, NL, PL [ii] Table DRD-1 part ii 15 countries with >=80%: EE, IE, LU, AT, PT, HR, CY, HU, MT, RO, FI, SE, UK, HR, TR, NO [iii] Table DRD-1 part ii 6 countries with >80%: EE, IE, LU, AT, PT, HR 80% males. Men account for most overdose deaths reported in Europe (80% overall). Patterns differ between countries, with a higher proportion of males reported in southern countries (Greece, Italy, Romania, Portugal, Croatia) and in Estonia, Latvia and Lithuania, as well as in Turkey. In the Member States that joined the EU since 2004, reported drug-induced deaths are also more likely to occur among males and in younger people. Polydrug use for example in Rome’s report - Scotland investigation 97% of the OD cases have several substances,, and in DN more than 3. In Ireland lots with BZD, as well as in NO. The overall picture is of frequent involvment of mixing drugs. Some cultural particularities as well, linked to the availability of the substances (e.g. methadone diverted) and to the culture e.g. Alcohol in Ireland Mortality rates due to overdose.

Population rates of drug-induced deaths show North-South gradient More detailed analyses suggest that this mainly reflects regional differences in problem drug use prevalence.

Increasing average age of drug overdose victims (22-year trend) Increases in drug-induced deaths reported in Europe in 2014 and 2015, by age-band Over these 22 tears, from 1990s til 2012, the mean age of the OD victims has increased from lbeing in the late 20s to the late 30s in many (old EU) pre-2004 countries But deaths not just among the oder users: between 2014 ad 2015, the number of deaths in almost all age bands has increased.

Age pyramids of overdose cases – different country situations and populations at risk: e.g. Germany – Ireland – Estonia – Norway, 2011/12 Gender and age distribution vary between countries. Overall 8 in 10 cases are males - blue An illustration of the various profiles of DUs, e.g. in EE, relatively youger, vast majority injecting, small proportion of women

Context of THN programmes Europe Effective treatment scaled up: >50% POUs in opioid substitution treatment; Ongoing increase of overdose deaths since 2012. Heroin using populations in Europe are ageing and physically vulnerable. Number of deaths increases across most age groups. Synthetic opioids play increasing role. more than 7500 overdoses in 2015 in the EU; after decrease, a newly increasing trend since 2012; drug-related mortality 1-2%; Interventions directed at: reducing vulnerability;

Interventions to reduce the risk of opioid-related deaths reducing the risk of overdoses to occur; and reducing mortality of overdoses

Interventions in place in European countries that can reduce opioid-related deaths

Scaling up of TH-Naloxone: snapshot TH-NLX in 10 countries: DK, EE, DE, FR, IE, IT, ES, (LT), NO, UK. INSERT FIGURE TIMELINE HERE

Performance … and lots of diversity 53.000 doses/kits given out; Scotland 55%, Wales 20% 20.000 people trained*, of which 6.000 last year *except Italy, Berlin, Scotland Local”fit”: large variation in the characteristics of programmes

Barriers for THN coverage Legal/regulatory barriers prescription-only use limited to medically trained personnel handling & storage restricted Formulation Injectable (IV, IM, SC) use of syringe an obstacle? ‘off-label’ IN use in some THN projects Nasal spray/applicator now developed but not yet available in most EU countries

Challenges A main challenge for take-home naloxone programmes is to achieve sufficient coverage of the at risk populations so that substantial reductions in opioid overdose deaths can be attained. Intranasal (injection-free) formulations are entering the market may facilitate paradigmatic shifts: (less need for training, less risk of injury, etc), removal of prescription requirement (e.g. Canada)….

www.emcdda.europa.eu